Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete \>1 gram (gm) of protein per day despite standard of ca...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Alnylam Pharmaceuticals
NCT06858319 · Kidney Diseases, Kidney Diseases, Chronic, and more
NCT07305116 · Autoimmune Diseases, Systemic Lupus Erthematosus (SLE), and more
NCT01802034 · Kidney Diseases, Kidney Failure, Chronic, and more
NCT06654596 · IgA Nephropathy (IgAN), Kidney Diseases, and more
NCT05510323 · Glomerulonephritis, IGA
Clinical Trial Site
Vancouver, British Columbia
Clinical Trial Site
Brampton, Ontario
Clinical Trial Site
Toronto, Ontario
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions